Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

被引：2
|
作者：
Lemelin, A. [1 ]
Takemura, K. [2 ]
Boyne, D. J. [3 ]
Warkentin, M. T. [3 ]
Brenner, D. R. [3 ]
Cheun, W. Y. [3 ,6 ]
Wells, J. C. [4 ]
Labaki, C.
McGregor, B. A. [6 ]
Basappa, N. S. [7 ]
Meza, L. A. [8 ]
Pal, S. K. [8 ]
Beuselinck, B. [9 ]
Mckay, R. R. [10 ]
Szabados, B. E. [11 ]
Powles, T. B. [12 ]
Yuasa, T. [13 ]
Ludwig, L. [14 ]
Choueiri, T. K. [5 ]
Heng, D. Y. C. [2 ]
机构：
[1] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Oncol Dept, Calgary, AB, Canada
[3] Univ Calgary, Oncol Dept, Oncol, Calgary, AB, Canada
[4] BC Canc Agcy, Oncol, Vancouver, BC, Canada
[5] Dana Farber Canc Inst, Med Genet Unit, Boston, MA USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[7] Cross Canc Inst, Med Oncol Dept, Edmonton, AB, Canada
[8] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[9] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium
[10] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[11] Barts & London Queen Marys Sch Med & Dent, Med Oncol Dept, Canc Res UK Barts Ctr, London, England
[12] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England
[13] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[14] Ipsen Biopharmaceut Canada Inc, Med Sci Liaison, Mississauga, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1902P
引用
收藏
页码：S1023 / S1024
页数：2
相关论文
共 50 条
  • [41] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (mNSCLC): Results from CheckMate 227
    Reck, Martin
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Paz-Ares, Luis
    Borghaei, Hossein
    O'byrne, Kenneth John
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 162 - 162
  • [42] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648
    Greil, R.
    Kato, K.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. Ignez
    Holtved, E.
    Murphy, M. Blum
    Patel, A.
    Hu, N.
    Matsumura, Y.
    Chau, I
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 242 - 243
  • [43] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648
    Chau, Ian
    Ajani, Jaffer A.
    Kitagawa, Yuko
    Xu, Jianming
    Wyrwicz, Lucjan S.
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez
    Holtved, Eva
    Murphy, Mariela A. Blum
    Nathani, Raheel
    Hu, Nan
    Matsumura, Yasuhiro
    Kato, Ken
    Doki, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Labaki, Chris
    Bakouny, Ziad
    Lemelin, Audreylie
    Ernst, Matthew Scott
    Takemura, Kosuke
    Wells, J. Connor
    Pal, Sumanta Kumar
    Szabados, Bernadett
    Beuselinck, Benoit
    McKay, Rana R.
    Lee, Jae-Lyun
    Yuasa, Takeshi
    Parnis, Francis
    Bjarnason, Georg A.
    McGregor, Bradley Alexander
    Braun, David A.
    Xie, Wanling
    Xu, Wenxin
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
    Kato, Ken
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Patel, Apurva
    Hu, Nan
    Matsumura, Yasuhiro
    Chau, Ian
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 290 - 290
  • [46] Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study.
    Hutson, Thomas E.
    Liu, Frank Xiaoqing
    Pandya, Shivani
    Dieyi, Christopher
    Kim, Ruth
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Nivolumab (NIVO) plus ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Caro, R. B.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S3
  • [48] Head-to-head comparison of first-line FOLFIRINOX versus gemcitabine plus nabpaclitaxel (GN) in advanced pancreatic cancer (APC): A target trial emulation using Canadian real-world data.
    Boyne, Devon J.
    Brenner, Darren
    Gupta, Alind
    Mackay, Eric
    Arora, Paul
    Wasiak, Radek
    Cheung, Winson Y.
    Hernan, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
    Adenis, A.
    Chau, I.
    Ajani, J. A.
    Kitagawa, Y.
    Xu, J.
    Wyrwicz, L. S.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C-H.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. I.
    Holtved, E.
    Murphy, M. Blum
    Zhang, J.
    Hu, N.
    Matsumura, Y.
    Kato, K.
    Doki, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S161 - S162
  • [50] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
    Paz-Ares, Luis G.
    Ciuleanu, Tudor-Eliade
    Cobo-Dols, Manuel
    Bennouna, Jaafar
    Cheng, Ying
    Mizutani, Hideaki
    Lingua, Alejo
    Reyes, Felipe
    Reinmuth, Niels
    De Menezes, Juliana Janoski
    Jassem, Jacek
    Protsenko, Svetlana
    Feeney, Kynan
    Jimenez, Emmanuel De La Mora
    Lu, Shun
    John, Tom
    Carbone, David Paul
    Zhang, Xiaoqing
    Hu, Nan
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
12345